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Immune responses by differentiated effector Th1, 
Th2, and Th17 cell subsets provide protection 
against pathogens but can also lead to chronic 
inflammation, autoimmunity, or allergy if not 
tightly controlled (Reiner, 2007; Steinman, 
2007). Critical controllers of these responses 
are immunosuppressive cytokines, such as IL-10 
and TGF-1, and regulatory T lymphocytes. 
Subsets of regulatory T cells suppress responses by 
other effector Th cells mainly via cell-to-cell in-
teractions (Nakamura et al., 2001) or the release 
of immunosuppressive cytokines (Asseman et al., 
1999; Chen et al., 2003; Hawrylowicz and 
O’Garra, 2005; Ostroukhova et al., 2006; Li 
et al., 2007). However, blockade of these cyto-
kines does not completely inhibit immune 
regulation (von Boehmer, 2005; Tang and 
Bluestone, 2008; Vignali et al., 2008), suggest-
ing that other, as yet unidentified, cytokines 
are also involved.
The cytokine activin-A, a member of the 
TGF- superfamily, participates in essential bi-
ological processes, such as development, hema-
topoiesis, wound repair, and fibrosis (Vale et al., 
CORRESPONDENCE  
Georgina Xanthou:  
gxanthou@bioacademy.gr
Abbreviations used: Act-RIIA, 
activin receptor type IIA; AHR, 
airway hyperresponsiveness; 
ALK, activin-like kinase; alum, 
aluminum hydroxide; BAL, 
bronchoalveolar lavage; DLN, 
draining LN; EAE, experimen-
tal autoimmune encephalomy-
elitis; FEV1, forced expiratory 
volume in 1 s; Foxp3, forkhead 
box p3; H&E, hematoxylin and 
eosin; PAS, periodic acid–Schiff; 
PenH, enhanced pause; r-ac-
tivin-A, recombinant activin-A. T. Alissafi and M. Aggelakopoulou contributed equally to 
this paper.
V. Panoutsakopoulou and G. Xanthou contributed equally to 
this paper.
Activin-A induces regulatory T cells  
that suppress T helper cell immune responses 
and protect from allergic airway disease
Maria Semitekolou,1 Themis Alissafi,1 Maria Aggelakopoulou,1  
Evangelia Kourepini,1 Harsha H. Kariyawasam,2,3,4 Antony B. Kay,2,3,4 
Douglas S. Robinson,2,3,4 Clare M. Lloyd,4 Vily Panoutsakopoulou,1  
and Georgina Xanthou1
1Cellular Immunology Laboratory, Center for Basic Research, Biomedical Research Foundation of the Academy of Athens, 
Athens 11527, Greece
2Medical Research Council and Asthma UK Centre in Allergic Mechanisms of Asthma, London EC2A 2DB, England, UK
3Allergy and Clinical Immunology Section and 4Leukocyte Biology Section, National Heart and Lung Institute, Faculty  
of Medicine, Imperial College, London SW7 2AZ, England, UK
Activin-A is a pleiotropic cytokine that participates in developmental, inflammatory, and 
tissue repair processes. Still, its effects on T helper (Th) cell–mediated immunity, critical for 
allergic and autoimmune diseases, are elusive. We provide evidence that endogenously 
produced activin-A suppresses antigen-specific Th2 responses and protects against airway 
hyperresponsiveness and allergic airway disease in mice. Importantly, we reveal that ac-
tivin-A exerts suppressive function through induction of antigen-specific regulatory T cells 
that suppress Th2 responses in vitro and upon transfer in vivo. In fact, activin-A also sup-
presses Th1-driven responses, pointing to a broader immunoregulatory function. Blockade 
of interleukin 10 and transforming growth factor 1 reverses activin-A–induced suppres-
sion. Remarkably, transfer of activin-A–induced antigen-specific regulatory T cells confers 
protection against allergic airway disease. This beneficial effect is associated with dramati-
cally decreased maturation of draining lymph node dendritic cells. Therapeutic administra-
tion of recombinant activin-A during pulmonary allergen challenge suppresses Th2 
responses and protects from allergic disease. Finally, we demonstrate that immune cells 
infiltrating the lungs from individuals with active allergic asthma, and thus nonregulated 
inflammatory response, exhibit significantly decreased expression of activin-A’s responsive 
elements. Our results uncover activin-A as a novel suppressive factor for Th immunity and a 
critical controller of allergic airway disease.
© 2009 Semitekolou et al. This article is distributed under the terms of an Attri-
bution–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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RESULTS
Depletion of activin-A during allergen challenge  
in the airways enhances Th2 allergic responses  
and exacerbates asthmatic disease
We initially investigated the in vivo role of activin-A in Th-
mediated responses and, more specifically, in Th2-associated 
allergic airway inflammation, as activin-A is expressed during 
Th2-driven allergic responses (Rosendahl et al., 2001; Hardy 
et al., 2006; Karagiannidis et al., 2006). For this, we adminis-
tered a neutralizing antibody to activin-A (or Ig control) 
right before pulmonary allergen (OVA) challenge of OVA/
aluminum hydroxide (alum)–sensitized mice (experimental 
protocol described in Fig. 1 A).
Depletion of activin-A during pulmonary allergen chal-
lenge resulted in significant exacerbation of allergic airway 
disease. This was shown by significantly increased total 
numbers of BAL-infiltrating cells and eosinophils, a hall-
mark of allergic airway disease (Humbles et al., 2004; Lee et al., 
2004), as compared with Ig treatment (Fig. 1 B). More im-
portantly, airway hyperresponsiveness (AHR) to increasing 
doses of inhaled methacholine, a clinical measurement of 
the asthmatic phenotype, was also significantly worsened 
in mice treated with anti–activin-A (Fig. 1 C). PBS/alum-
sensitized and OVA-challenged mice (alum controls) ex-
hibited lower AHR responses in comparison to the other 
groups (Fig. 1 C). Moreover, pulmonary inflammation and 
mucus secretion were significantly increased in mice treated 
with anti–activin-A (Fig. 1 D). The increase in eosinophilic 
infiltration, observed upon activin-A depletion at challenge, 
was accompanied by significantly increased expression of 
the eosinophil-specific chemokine CCL11 in lung homog-
enates (Fig. 1 G).
We also examined the effects of in vivo neutralization 
of activin-A on OVA-specific Th2-mediated effector re-
sponses by measuring Th cell proliferation and cytokine re-
lease in the supernatants of draining LN (DLN) cell cultures 
stimulated ex vivo with OVA. There was significantly in-
creased OVA-specific Th cell proliferation and significantly 
increased production of the Th2 cytokines IL-4, IL-13, 
and IL-10 in stimulation cultures of DLN cells from mice 
treated with anti–activin-A, as compared with Ig controls 
(Fig. 1 E). IFN- levels in culture supernatants were also 
significantly increased, possibly resulting from the overall 
enhanced inflammation (Fig. 1 E). In support, we observed 
significantly increased lung and BAL levels of IL-4, IL-13, 
and IL-10 concomitant with decreased production of IL-12 
and IL-17, cytokines considered protective when overex-
pressed in the lungs of allergic mice (Walter et al., 2001; 
Schnyder-Candrian et al., 2006) upon activin-A depletion 
in vivo (not depicted). OVA-specific IgE and IgG1 (Th2 
isotypes) serum concentrations were significantly increased 
(Fig. 1 F), whereas OVA-specific IgG2a (Th1 isotype) lev-
els were decreased (Fig. 1 F).
No differences were observed in the recruitment of ef-
fector T1/ST2+ Th2 cells among CD3+CD4+ Th cells in 
the DLNs and lungs between anti–activin-A– and Ig-treated 
1988; Werner and Alzheimer, 2006). Activin-A/ mice are 
embryonic lethal (Matzuk et al., 1995b), whereas activin recep-
tor type IIA (act-RIIA)/ mice reach adulthood but have ma-
jor deficiencies in their reproductive systems (Matzuk et al., 
1995a). Although most studies have focused on the role of 
activin-A in developmental and fibrotic processes, certain re-
ports demonstrate elevated levels of this cytokine in immune-
mediated diseases such as rheumatoid arthritis (Ota et al., 
2003) and inflammatory bowel disease (Hubner et al., 1997; 
Dohi et al., 2005). Activin-A is also increased in the sera of 
individuals with allergic asthma (Karagiannidis et al., 2006), 
and in the lung and bronchoalveolar lavage (BAL) of mice 
during acute (Rosendahl et al., 2001; Hardy et al., 2006) and 
chronic allergic airway inflammation and remodeling (Le 
et al., 2007). In addition, activin-A is induced in human 
(Karagiannidis et al., 2006) and mouse effector Th2 lympho-
cytes (Ogawa et al., 2006), which are key players in allergic 
responses. However, whether activin-A has enhancing or 
suppressive actions during Th immune responses and subse-
quent disease remains unclear.
Certain studies indicate that recombinant activin-A 
(r-activin-A) reduces in vitro nonspecific proliferation of human 
Th (Karagiannidis et al., 2006) and mouse B cells (Yu et al., 
1998; Werner and Alzheimer, 2006), and inhibits certain 
functions of human natural killer cells (Robson et al., 2009). 
In other reports, r-activin-A attenuates in vitro endotoxin-
induced maturation and phagocytosis of mouse macrophages 
(Wang et al., 2008; Zhou et al., 2009) and CD40 ligand– 
dependent cytokine and chemokine release by human mono-
cytes and DCs (Robson et al., 2008). Nevertheless, a few reports 
have suggested that activin-A has proinflammatory effects, i.e., 
during in vivo endotoxin administration and allergen challenge 
in mice (Hardy et al., 2006; Jones et al., 2007). Collectively, 
these studies indicate a dual nature of this cytokine, a charac-
teristic feature of certain immune mediators (Veldhoen et al., 
2006; Zenewicz et al., 2008). Of note, our previous studies re-
vealed a dual role for another cytokine, osteopontin, in allergic 
airway inflammation (Xanthou et al., 2007).
In the present study, we have investigated the in vivo role 
of activin-A in Th-mediated immune responses and, more 
specifically, during Th2-associated allergic airway inflamma-
tion. We demonstrate that antibody-mediated depletion of 
activin-A during pulmonary allergen challenge resulted in 
significant exacerbation of Th2-mediated allergic airway dis-
ease, indicating that endogenous activin-A is suppressive. In 
fact, our findings reveal that activin-A induces the generation 
of antigen-specific regulatory T cells that suppress both pri-
mary and effector Th responses in vitro and upon adoptive 
transfer in vivo. Functional in vitro analysis shows that ac-
tivin-A–mediated suppressive effects on Th responses are 
dependent on both IL-10 and TGF-1. Importantly, activin-
A–induced antigen-specific regulatory T cells transfer protec-
tion against allergic airway disease correlated with decreased 
DC maturation. Collectively, our data reveal that activin-A 
can suppress Th responses and represents a critical therapeutic 
target for allergic asthma.
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by increased Th2 effector cell trafficking but rather by an 
enhanced effector function of Th2 cells. To address this, we 
examined the effects of DLN cells obtained from anti– 
activin-A–treated mice (or Ig controls) on responses of co-
cultured OVA-specific T cell receptor transgenic Th cells 
mice (unpublished data). In support, levels of the Th2 cell–
recruiting chemokines CCL17 and CCL22 were not signifi-
cantly altered between the two groups (Fig. 1 G). This 
suggested that the overall increase in Th2-mediated allergic 
responses upon in vivo activin-A depletion was not caused 
Figure 1. In vivo depletion of activin-A during pulmonary allergen challenge exacerbates allergic airway disease and Th2 responses. (A) Experimen-
tal protocol used to block endogenous activin-A during pulmonary challenge. (B) BAL differentials from mice treated with anti–activin-A or Ig control, or from 
the alum controls are expressed as means ± SEM (n = 5–8 mice per group in four separate experiments). Statistical significance was obtained by an unpaired 
Student’s t test (*, P = 0.0345; **, P = 0.0476). (C) AHR is depicted. Results shown for PenH are expressed as means ± SEM (n = 5–8 mice per group in four sepa-
rate experiments). Data were analyzed by two-way analysis of variance (ANOVA) for repeated measures, followed by an unpaired Student’s t test (*, P = 0.0164; 
**, P = 0.00047). (D) Representative photomicrographs demonstrating lung inflammation (H&E-stained sections) and mucus secretion (PAS-stained sections). 
Histological scores of H&E-stained (***, P = 0.0009) and PAS-stained (***, P < 0.0001) sections. Error bars depict means of groups (n = 5–8 mice per group in four 
independent experiments). Bars, 100 µm. (E) DLN cells were restimulated ex vivo with OVA. Proliferation was measured by [3H]thymidine incorporation. Results 
are shown as means ± SEM of triplicate wells (n = 5–8 mice per group in four independent experiments; ***, P < 0.0001). IL-4 (***, P < 0.0001), IL-13 (***, P < 
0.0001), IL-10 (***, P < 0.0001), and IFN- (***, P < 0.0001) in supernatants are shown. Results are means ± SEM of duplicate wells (n = 5–8 mice per group in 
four independent experiments). (F) OVA-specific IgE (**, P = 0.0060), IgG1 (*, P = 0.0165), and IgG2a (*, P = 0.0218) in the sera of mice. Results are means ± SEM 
(n = 5–8 mice per group in four independent experiments). (G) CCL11 (**, P = 0.0054), CCL17 (P = 0.9399), and CCL22 (P = 0.5000) in lung homogenates are 
shown. Results are means ± SEM (n = 5–8 mice per group in four separate experiments). (H) DLN cells from anti–activin-A– or Ig–treated mice were co-cultured 
with LN KJ1-26+CD4+ T cells (2:1) in the presence of OVA323-339 peptide, and proliferation was measured (**, P = 0.001). The results are means ± SEM (n = 5–8 
mice per group in two independent experiments). Eos, eosinophils; LMs, lymphomononuclears; Macs, macrophages; Neuts, neutrophils.
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the OVA323-339 peptide and induced increased production of 
IL-10 (not depicted). We and other investigators have found 
that activin-A is produced during primary Th responses (50–
500 pg/ml in Th stimulation cultures; Ogawa et al., 2006). As 
anticipated, addition of a neutralizing antibody to block endog-
enously produced activin-A resulted in significantly increased 
proliferation of KJ1-26+CD4+ T cells during OVA-driven 
stimulation, concomitant with decreased IL-10 levels, as com-
pared with Ig treatment (a two- and fourfold increase, respec-
tively). Similar results were obtained when ALK4 was blocked 
(a two- and threefold increase, respectively), indicating that the 
suppressive effects of activin-A were mainly mediated by ALK4. 
Hence, activin-A suppresses both primary and effector antigen-
specific Th2 responses in vitro and renders Th2 effector cells 
hyporesponsive to immunization in vivo.
Activin-A induces the generation of regulatory CD4+ T cells 
that are suppressive in vitro and in vivo
Subsequently, we investigated whether activin-A–mediated 
Th suppression is associated with induction of T cells with 
regulatory/suppressive function. To address this, we per-
formed an in vitro suppression assay wherein we co-cultured 
activin-A–treated CD4+ T cells with untreated T cells (KJ1-
26+CD4+ T cells) and examined the responses of the latter 
cells to the OVA323-339 peptide. r-activin-A–treated OVA-
primed Th2 cells significantly suppressed the proliferation of 
KJ1-26+CD4+ T cells to the OVA323-339 peptide (Fig. 3 A). 
KJ1-26+CD4+ T cells cultured alone exhibited much higher, 
compared with the other groups, antigen-specific prolifera-
tive responses (120,000 cpm). Moreover, r-activin-A–
treated T cells significantly inhibited IL-4 and IL-13 release 
from responder KJ1-26+CD4+ T cells (Fig. 3 B). Treatment 
with TGF-1, a well-known immunosuppressive cytokine 
(Chen et. al., 2003; Li et. al., 2007), also conferred inhibitory 
effects on OVA-primed Th2 cells. This was shown by signif-
icantly decreased antigen-specific proliferation and cytokine 
release from responder KJ1-26+CD4+ T cells after co-culture 
with TGF-1–treated cells (Fig. 3, A and B). Overall, r-activin-
A–treated antigen (OVA)-specific Th2 cells had essential fea-
tures of regulatory T cells; i.e., they were suppressed during 
antigenic stimulation and suppressive toward antigen-driven 
responses of other Th cells in vitro.
Next, we examined whether r-activin-A–treated CD4+ 
T cells were also suppressive toward responses by other Th 
cells in vivo. For this, we performed an in vivo suppression 
assay wherein we adoptively cotransferred r-activin-A (or 
PBS)–treated OVA-primed CD4+ T cells along with un-
treated KJ1-26+CD4+ T cells into recipient BALB/c-Rag1/ 
mice and examined antigen-specific responses of KJ1-
26+CD4+ T cells after immunization with OVA in alum (ex-
perimental protocol described in Fig. 3 C). Flow cytometry 
revealed that r-activin-A– but not PBS-treated OVA-primed 
CD4+ T cells decreased OVA-specific expansion of KJ1-
26+CD4+ T cells in DLNs of recipient mice (Fig. 3 D). More 
importantly, r-activin-A–treated CD4+ T cells suppressed the 
ex vivo proliferation of DLN KJ1-26+CD4+ T cells to the 
from DO11.10 mice (recognized by expression of the clo-
notypic receptor by the antibody KJ1-26 and hereafter re-
ferred to as KJ1-26+) to the OVA323-339 peptide. Indeed, 
DLN cells from anti–activin-A–treated mice lead to signifi-
cantly increased proliferation of KJ1-26+CD4+ T responders 
to the OVA323-339 peptide (Fig. 1 H). These data further sup-
port decreased immune regulation upon blockade of endog-
enously produced activin-A in vivo. Overall, antibody- 
mediated depletion of activin-A during pulmonary allergen 
challenge enhanced allergen-specific Th2 responses and ex-
acerbated allergic airway disease.
Activin-A suppresses antigen-specific primary  
and effector Th2 responses
Effector Th2 cell–mediated responses are essential for the de-
velopment of allergic airway inflammation and asthmatic dis-
ease. Thus, we hypothesized that activin-A protects against 
allergic airway inflammation through suppression of antigen-
specific Th2 effector responses. To examine this, we isolated 
OVA-primed Th2 effector cells from DLNs of allergic mice 
(sensitized with OVA/alum and challenged with OVA) and 
restimulated them ex vivo with OVA in the presence of r-ac-
tivin-A or PBS (control). Indeed, r-activin-A treatment sup-
pressed responses of OVA-primed Th2 effector cells, as shown 
by significantly decreased OVA-specific proliferation (Fig. 2 A) 
and significantly decreased concentrations of supernatant Th2 
cytokines (Fig. 2 A). Similar to what was observed for IL-4 
and IL-13, r-activin-A significantly decreased IL-10 produc-
tion because, in this setting of Th2 effector responses, IL-10 
operates mainly as a Th2 cytokine. In support, using the re-
verse approach, we demonstrated that blockade of either en-
dogenously expressed activin-A or its critical signaling receptor, 
activin-like kinase (ALK) 4, resulted in significantly increased 
levels of IL-4, IL-13, and IL-10, and enhanced Th2 cell pro-
liferation, as compared with Ig treatment (not depicted).
We subsequently investigated whether r-activin-A treat-
ment of Th2 effector cells would also render them suppressed 
during antigenic stimulation in vivo. To address this, r-ac-
tivin-A– or PBS-treated Th2 effector cells were adoptively 
transferred into BALB/c-Rag1/ recipient mice, which were 
later immunized with OVA in alum (experimental protocol 
described in Fig. 2 B). Adoptively transferred r-activin-A–
treated Th2 effector cells retained a suppressed phenotype 
after in vivo antigenic stimulation, as shown by significantly 
decreased antigen-specific proliferation (Fig. 2 B).
Subsequently, we investigated activin-A’s effects on pri-
mary antigen-driven Th responses. We isolated LN KJ1-
26+CD4+ T cells and stimulated them in vitro with antigen in 
the presence of r-activin-A. Treatment with r-activin-A re-
sulted in significantly decreased OVA-induced proliferation of 
KJ1-26+CD4+ T cells (Fig. 2 C). In addition, IL-4 levels were 
decreased during r-activin-A treatment as compared with con-
trol (Fig. 2 C). The suppressive effect of r-activin-A was ac-
companied by significantly increased production of IL-10 
(Fig. 2 C). Similarly, r-activin-A also significantly suppressed 
the robust proliferative responses of KJ1-26+CD4+ T cells to 
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this cytokine can also affect anti-CD3–driven T cell ac-
tivation. Purified CD4+ T cells were stimulated with 
anti-CD3 in the presence of r-activin-A or PBS. Similar 
to our observations for Th2 effector responses, r-activin-A 
treatment also suppressed anti-CD3–driven Th stimulation, as 
shown by significantly reduced proliferation (Fig. 4 A) and 
IL-2 release (Fig. 4 A). Interestingly, activin-A–mediated 
suppression was accompanied by increased production of 
IL-10, a cytokine considered immunoregulatory in the 
context of, except for Th2, T cell responses (Fig. 4 A; 
Hawrylowicz and O’Garra, 2005). The immunosuppressive 
effects of activin-A were not caused by toxicity, as flow 
cytometry studies showed no increases in annexin V+ cells 
(not depicted). In fact, addition of rIL-2 reversed r-activin-
A–mediated suppression of Th cell proliferation (Fig. 4 B). 
This also indicated that activin-A renders Th cells aner-
gic. Notably, r-activin-A treatment also suppressed antigen 
(OVA)-specific in vitro proliferation of Th1 effector cells 
(obtained from DLNs of CFA/OVA-immunized mice; Fig. 
4 C). Collectively, our results reveal that activin-A not only 
suppresses Th2 cell–associated responses but also inhibits 
Th1 cell activation.
OVA323-339 peptide, as shown by significantly decreased pro-
liferation of DLN cells from mice that received r-activin-A–
treated CD4+ T cells as compared with DLN cells from 
recipients of PBS-treated controls (Fig. 3 E). TGF-1–treated 
CD4+ T cells also inhibited OVA-specific expansion and 
proliferation of KJ1-26+CD4+ T cells in DLNs of recipient 
mice (Fig. 3, D and E). We also observed significantly de-
creased IL-4 and IL-13 levels in the supernatants of OVA323-339–
stimulated responder KJ1-26+CD4+ T cells in DLNs obtained 
from mice that received either r-activin-A– or rTGF-1–
treated CD4+ T cells (Fig. 3 F). It was not surprising that 
IL-10 remained unaltered, as this cytokine also functions 
as a Th2 cytokine in this setting. Hence, using both in vitro 
and in vivo suppression assays, we demonstrate that activin-A 
induces the generation of antigen-specific regulatory T cells 
that are suppressive toward responses of Th2 effector cells in 
vitro and upon adoptive transfer in vivo.
Activin-A–induced suppression of Th responses is mediated 
by both IL-10 and TGF-1
Our studies so far have shown that activin-A suppresses 
antigen-driven Th responses. We next investigated whether 
Figure 2. Activin-A suppresses antigen-specific primary and effector Th2 responses. (A) DLN cells were harvested from OVA/alum-immunized 
and OVA-challenged BALB/c mice, and proliferation was measured after ex vivo OVA restimulation in the presence of PBS (designated as control) or  
r-activin-A (*, P = 0.0121). Results are shown as means ± SEM from four separate experiments. Statistical significance was obtained by an unpaired  
Student’s t test. IL-4 (**, P = 0.0070), IL-13 (*, P = 0.0103), and IL-10 (**, P = 0.0081) in supernatants are shown. (B) DLN cells from OVA/alum-immunized 
BALB/c mice were restimulated ex vivo with OVA in the presence of PBS or r-activin-A. CD4+ T cells were adoptively transferred into BALB/c-Rag1/ 
recipients. Proliferation of DLN cells to OVA from mice that received CD4+ T cells treated with PBS or r-activin-A (***, P < 0.0001). The results are means ± 
SEM of triplicate wells (n = 4–6 mice per group in two separate experiments). Statistical significance was obtained as described. (C) KJ1-26+CD4+ T cells 
were stimulated with OVA and irradiated APCs as indicated. Proliferation was measured (***, P < 0.0001). IL-4 (**, P = 0.0038) and IL-10 (**, P = 0.0073) are 
shown. Results are means ± SEM of triplicate wells from four separate experiments.
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IL-10, using an antibody against IL-10R, partially reversed r-
activin-A–mediated suppression of proliferative Th effector 
responses (Fig. 4 D). Similarly, anti–IL-10R treatment partially 
reversed the suppressive effect of r-activin-A on antigen-driven 
As our studies have demonstrated an increased produc-
tion of IL-10 under certain immune settings (Figs. 2 C and 
4 A), we next investigated the potential role of this cytokine 
in the immunosuppressive effects of activin-A. Blocking of 
Figure 3. Activin-A induces the generation of antigen-specific regulatory CD4+ T cells. (A) DLN cells from OVA/alum-immunized BALB/c mice 
were restimulated ex vivo with OVA in the presence of PBS, r-activin-A, or rTGF-1. CD4+ T cells were co-cultured with KJ1-26+CD4+ T cells (2:1) in the 
presence of irradiated APCs and OVA323-339 peptide. Proliferation is shown (***, P < 0.0001; **, P = 0.0010). Results are shown as means ± SEM of triplicate 
wells in two independent experiments. Statistical significance was calculated by an unpaired Student’s t test. (B) IL-4 (**, P < 0.0001; ***, P < 0.0001), IL-13 
(***, P < 0.0001; **, P = 0.0007), and IL-10 (P = 0.9903; P = 0.0815) in supernatants are shown. Results are means ± SEM of duplicate wells in two separate 
experiments. Statistical significance was calculated as described. (C) r-activin-A–, rTGF-1–, or PBS-treated CD4+ T cells (obtained as in A) were adoptively 
transferred along with KJ1-26+CD4+ T cells (1:1) into BALB/c-Rag1/ recipients. Recipients were immunized with OVA/alum, and DLN cells were har-
vested. (D) Flow cytometry panels of gated CD4+ T cells from recipients stained for KJ1-26. Absolute numbers of CD4+KJ1-26+ T cells in DLNs of recipients 
(**, P < 0.0001; ***, P < 0.0001). Values are means ± SEM (n = 4–6 mice per group in two separate experiments). (E) Proliferation of DLN cells from recipi-
ent mice to OVA323-339 peptide is shown (**, P < 0.0001; ***, P < 0.0001). The results are means ± SEM (n = 4–6 mice per group from two separate experi-
ments). (F) IL-4 (**, P < 0.0001; ***, P < 0.0001), IL-13 (***, P < 0.0001; **, P = 0.0001), and IL-10 (P = 0.5253; P = 0.7871) in supernatants. Results are 
means ± SEM (n = 4–6 mice per group from two separate experiments).
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primary responses of KJ1-26+CD4+ T cells so that r-activin-
A– and anti–IL-10R–treated cells exhibited similar prolifera-
tion to PBS and anti–IL-10R–treated cells (132,300 ± 6,515 
cpm for PBS- and anti–IL-10R–treated cells vs. 120,300 ± 
7,752 cpm for r-activin-A– and anti–IL-10R–treated cells). 
However, blockade of IL-10 did not significantly affect ac-
tivin-A–induced suppression of IL-2 release (Fig. 4 D). Im-
portantly, blocking of IL-10 also partly reversed the 
suppressive effects of r-activin-A–induced CD4+ regulatory 
T cells (OVA-primed Th cells) on the proliferation of KJ1-
26+CD4+ responder T cells (unpublished data).
As blocking of IL-10 did not completely reverse the in-
hibitory effects of activin-A on Th responses, we hypothe-
sized that other immunosuppressive cytokines (such as TGF-1) 
may also be involved. Addition of a blocking antibody against 
TGF-1 partially reversed activin-A–mediated suppression 
of Th cell proliferation, whereas it inhibited the suppression 
of IL-2 release (Fig. 4 D). Notably, addition of both anti–IL-
10R and anti–TGF-1 antibodies completely reversed ac-
tivin-A–induced suppression of Th responses, indicating a 
synergistic effect.
Examination of the phenotype of the activin-A–induced 
regulatory T cells revealed that these cells lacked expression 
of Forkhead box p3 (Foxp3), the transcription factor that 
drives differentiation of certain regulatory T cell subsets 
(Fontenot et al., 2003; Hori et al., 2003; Vignali et al., 2008). 
In fact, flow cytometry analysis of anti-CD3–stimulated 
CD4+ T cells showed that there were no differences in the 
frequency of Foxp3+CD25+CD4+ T cells after r-activin-A 
treatment as compared with control (280,300 ± 15,150 
cells for r-activin-A vs. 335,200 ± 18,950 cells for PBS). 
In contrast, rTGF-1 treatment induced a greater number 
of Foxp3+CD4+ T cells (546,700 ± 20,280 cells; Fig. 4 E) 
as compared with PBS treatment, as also previously de-
scribed (Chen et al., 2003; Fontenot et al., 2003; Davidson 
et al., 2007). In addition, r-activin-A treatment of sorted 
(CD4+CD25CD62L+) naive T cells from DO11.10 mice 
during stimulation with OVA323-339 peptide–loaded bone 
marrow–derived DCs did not induce increased numbers of 
CD4+Foxp3+ T cells (12,420 ± 2,133 cells for r-activin-A vs. 
14,600 ± 1,456 cells for PBS). Similarly, treatment with r-
activin-A during restimulation with OVA ex vivo of DLN 
cells obtained from OVA-primed BALB/c mice did not in-
duce significantly increase Foxp3 expression (34,570 ± 3,123 
cells for r-activin-A vs. 30,090 ± 2,827 cells for PBS treat-
ment). Also, activin-A treatment of DLN cells from immu-
nized DO11.10 mice during restimulation with OVA323-339 
peptide ex vivo did not induce a significant increase in Foxp3 
expression, as compared with PBS (30,700 ± 2,170 cells for 
r-activin-A vs. 28,250 ± 2,350 cells for PBS). Nevertheless, 
r-activin-A treatment of CD4+ T cells (stimulated with either 
anti-CD3 or antigen) resulted in an 2.5-fold induction of 
IL-10+CD4+ T cells as compared with PBS (Fig. 4 F). These 
findings are in agreement with the increased IL-10 levels in 
CD4+ T cell cultures upon r-activin-A treatment (Figs. 2 and 
4). However, rTGF-1-treatment did not significantly alter 
IL-10+CD4+ T cell numbers (not depicted), suggesting that, 
at least in our experimental settings, these two cytokines induce 
distinct regulatory T cell subsets. Collectively, our findings sug-
gest that activin-A can exert a broad immunosuppressive ef-
fect on Th effector responses in vitro that is dependent on 
both IL-10 and TGF-1 production.
Activin-A–induced regulatory T cells protect  
against allergic airway disease
We next asked whether activin-A–induced regulatory T cells 
can confer protection against Th-mediated disease in vivo. 
To address this, we adoptively transferred r-activin-A (or 
control)–treated CD4+ T cells (obtained as in Fig. 3) into 
BALB/c mice before OVA/alum immunization and OVA 
aerosol challenge (experimental protocol in Fig. 5 A). Re-
markably, transfer of r-activin-A–treated OVA-primed CD4+ 
T cells resulted in a significant attenuation of all cardinal fea-
tures of allergic airway disease (Fig. 5). This was demonstrated 
by significantly decreased total numbers of BAL cells and, 
notably, eosinophils in mice adoptively transferred with 
r-activin-A–treated OVA-primed CD4+ T cells as compared 
with mice transferred with control-treated CD4+ T cells 
(Fig. 5 B). More importantly, there was a dramatic decrease 
in AHR responses in mice that received r-activin-A–treated 
OVA-primed CD4+ T cells that reached levels similar to 
those of alum controls (Fig. 5 C). A significant decrease 
(approximately threefold in histological score) was also ob-
served in leukocytic infiltration (Fig. 5 D) and in mucus se-
cretion (approximately threefold; Fig. 5 D) in the lungs of 
mice transferred with r-activin-A–treated CD4+ T cells, as 
compared with controls.
In accordance, DLN cells obtained from mice adoptively 
transferred with r-activin-A–treated CD4+ T cells exhibited 
significantly decreased proliferation to OVA ex vivo (Fig. 5 E) 
and produced significantly decreased levels of supernatant 
IL-4, IL-13, and IL-10 (Fig. 5 E). More importantly, adop-
tive transfer of r-activin-A–treated CD4+ T cells significantly 
decreased OVA-specific IgE levels, a critical clinical feature 
of allergic disease (Fig. 5 F).
DCs are essential for the differentiation and activation of 
Th responses, and several studies have demonstrated that reg-
ulatory T cell subsets can suppress immune-mediated disease 
through inhibition of the antigen presentation machinery 
and/or maturation of DCs (Kim et al., 2007; O’Garra and 
Vieira, 2007; Sakaguchi and Powrie, 2007). Interestingly, ex-
amination of the MHC class II molecule I-Ad expression on 
DLN CD11c+ DCs showed a striking decrease (an approxi-
mately ninefold difference, as shown by the mean fluores-
cence intensity) in I-Ad expression on DCs from mice 
adoptively transferred with r-activin-A–treated CD4+ T cells, 
as compared with controls (Fig. 5 G). In support, we observed 
a decrease in CD86 expression (not depicted). Collectively, 
our data revealed that activin-A–induced antigen-specific reg-
ulatory T cells can protect from allergic airway disease after 
transfer in vivo, and this is associated with decreased matura-
tion of CD11c+ DCs in lung DLNs.
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Figure 4. Activin-A–induced suppression is partly dependent on IL-10 and TGF-1. (A) CD4+ T cells were stimulated with anti-CD3 and irradi-
ated APCs as indicated. Proliferation was measured. The results are means ± SEM of triplicate wells from at least three separate experiments. Statistical 
significance was obtained by an unpaired Student’s t test (***, P = 0.0009). IL-2 (***, P = 0.0004) and IL-10 (*, P = 0.0463) in supernatants are shown.  
(B) Proliferation of CD4+ T cells stimulated as in A in the presence of r-activin-A and rIL-2 as indicated (***, P < 0.0001; **, P = 0.0010; P = 0.9871). The 
results are means ± SEM of triplicate wells from three separate experiments. (C) DLN cells, obtained from OVA/CFA-immunized BALB/c mice, were stimu-
lated ex vivo with OVA as indicated. Proliferation was measured (***, P < 0.0001). The results are means ± SEM of triplicate wells from three independent 
experiments. (D) Proliferation of CD4+ T cells stimulated with anti-CD3 and irradiated APCs with PBS or r-activin-A, as indicated (*, P = 0.0054; **, P = 
0.0011; ***, P = 0.0012; ****, P = 0.0002). IL-2 (*, P = 0.0005; **, P = 0.0004; ***, P = 0.0003) in supernatants is shown. The results are means ± SEM from 
two separate experiments. (E) Stimulated (anti-CD3/CD28 with rIL-2) CD4+ T cells from PBS-, r-activin-A–, or TGF-1–treated cultures were stained and 
analyzed by flow cytometry. Numbers indicate percentages of CD4+ gated cells positive for CD25 and Foxp3. Values are expressed as means ± SEM from 
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two separate experiments. (F) CD4+ T cells, stimulated as in A, stained with antibodies to CD3, CD4, and IL-10. Representative dot plots showing CD4+IL-
10+ cells from cultures of PBS- or r-activin-A–treated cells. Numbers above boxed areas indicate the percentage of DLN cells in the outlined gate. Values 
are expressed as means ± SEM from two separate experiments. FS, forward scatter.
 
Administration of activin-A in vivo suppresses  
experimental allergic asthma
Based on our data on the suppressive roles of activin-A and 
activin-A–induced regulatory T cells on Th2 effector re-
sponses as well as on the effects of activin-A blockade during 
allergen challenge, we next examined whether administra-
tion of r-activin-A to sensitized mice would protect from 
disease induction. Indeed, systemic (i.p.) administration of 
r-activin-A to OVA/alum-immunized animals right before 
each OVA aerosol challenge resulted in significantly de-
creased total numbers of cells, and most importantly, eo-
sinophils in the BAL, as compared with treatment with PBS 
(Fig. 6 A). Moreover, AHR responses were significantly 
decreased in r-activin-A–treated mice and reached levels 
similar to those of alum controls (Fig. 6 B). A significant 
decrease (1.5-fold in histological score) was also observed 
in leukocytic infiltration (Fig. 6 C) and in mucus secretion 
(2-fold; Fig. 6 C) in the lungs of r-activin-A–treated mice, 
as compared with PBS controls.
Similarly, DLN cells obtained from mice treated with r- 
activin-A exhibited significantly decreased proliferation to OVA 
ex vivo (Fig. 6 D) and produced decreased levels of IL-4, 
IL-13, and IL-10, as compared with PBS-treated controls 
(Fig. 6 D). In addition, OVA-specific IgG1 and IgE levels were 
decreased, whereas IgG2a levels were increased after r-activin-A 
treatment (Fig. 6 E). Hence, administration of r-activin-A in 
Th2-primed mice during pulmonary allergen challenge is pro-
tective against allergic airway disease induction.
Decreased expression of activin-A signaling components  
in allergic asthma
Based on the aforementioned findings, one would expect 
that activin-A production would be down-regulated during 
aberrant inflammatory processes such as those occurring in 
allergic asthma. However, we observed increased activin-A 
expression in lung biopsies from individuals with mild asthma 
as compared with healthy volunteers (Fig. 7 A, left). Activin-
A expression was mainly localized in bronchial epithelial cells 
and subepithelial inflammatory cells (Fig. 7 A, bottom left). 
A significant increase in the percentage of activin-A+ bron-
chial epithelial cells, as well as in the numbers of activin-A+ 
subepithelial cells, was observed in lung biopsies from asth-
matics as compared with healthy volunteers (Fig. 7 B). Quite 
the opposite was evident regarding the expression of activin-
A’s type I receptor, ALK4, which was significantly decreased 
in subepithelial infiltrating inflammatory cells (Fig. 7 A, bot-
tom right; and Fig. 7 B). Additionally, the levels of Act-RIIA 
were significantly decreased, both in bronchial epithelial cells 
and in subepithelial inflammatory cells, in the lungs of asth-
matics (Fig. 7 B). Similarly, we detected decreased expression 
of Act-RIIB in the lungs of asthmatics (unpublished data). 
Thus, although activin-A is increased in asthmatic lungs, the 
expression of its receptors in infiltrating immune cells is 
markedly reduced, suggesting a down-regulation of its sig-
naling pathway that may lead to reduced suppression of the 
allergic inflammatory response.
DISCUSSION
Activin-A has been mainly studied in developmental, fibrotic, 
and monocyte-mediated inflammatory processes (Werner 
and Alzheimer, 2006). In the present study, our findings re-
veal that activin-A is a suppressive cytokine for Th-mediated 
immunity. In fact, we demonstrate for the first time, to our 
knowledge, that activin-A induces the generation of antigen-
specific regulatory T cells that suppress responses by effector 
Th2 cells and, more importantly, transfer protection against 
Th2-associated allergic airway disease in vivo. Notably, we 
show that activin-A–induced regulation also affects Th1-
driven responses, pointing to a broader immunosuppressive 
role for this cytokine.
Initially, our findings demonstrated that antibody-medi-
ated depletion of activin-A during the clinically relevant 
phase of pulmonary allergen challenge resulted in significant 
exacerbation of Th2-mediated allergic airway disease (includ-
ing increased AHR, BAL eosinophilia, Th2 cytokine and 
chemokine secretion, and OVA-specific systemic Th2 and 
antibody responses). Importantly, blockade of activin-A dur-
ing OVA challenge resulted in a rapid (only after three daily 
doses of anti–activin-A) exacerbation of all cardinal features 
of the asthmatic disease. This indicated that endogenously 
produced activin-A is protective against allergic Th2 cell–me-
diated responses in the lung. In support, we found that DLN 
cells from anti–activin-A–treated mice cultured with KJ1-
26+CD4+ T cells induced significantly heightened prolifera-
tive responses of the latter cells, pointing to decreased immune 
regulation. This was also evident by the significantly increased 
levels of Th2 cytokines. Concomitant up-regulation of IL-10 
in these cultures can be explained either by the amplified 
Th2-mediated response or by the activation of regulatory 
mechanisms that are struggling to control the enhanced in-
flammation. We cannot exclude the possibility of an activin-
A–mediated effect on lung epithelial and smooth muscle cells 
as well. Nevertheless, r-activin-A treatment of CD4+ T cells 
rendered them suppressive, as they inhibited Th2 effector cell 
responses when adoptively transferred in vivo. This latter ex-
perimental approach uncovered the effects of r-activin-A on 
immune cells only. In another study, activin-A neutralization 
in vivo by a mouse monoclonal antibody resulted in decreased 
antigen-specific IgE (Ogawa et al., 2008). The observed dif-
ferences could be caused by the fact that the investigators of 
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Figure 5. Activin-A–induced regulatory T cells protect from allergic airway disease upon transfer in vivo. (A) CD4+ T cells (obtained as in Fig. 3) 
were treated with either PBS or r-activin-A and adoptively transferred to BALB/c mice before OVA/alum immunization and OVA challenge. (B) BAL differen-
tials from mice that received r-activin-A– or PBS-treated CD4+ T cells, or from the alum controls. Results are expressed as means ± SEM (n = 5–7 mice per 
group in two separate experiments). Statistical significance was obtained by an unpaired Student’s t test (*, P = 0.0407; ***, P = 0.0007). (C) AHR is depicted. 
Results shown for PenH are expressed as means (n = 5–7 mice per group in two separate experiments). Data were analyzed by two-way ANOVA for repeated 
measures, followed by an unpaired Student’s t test (*, P = 0.0341; **, P = 0.0003; ***, P = 0.0004; ****, P = 0.0017). (D) Representative photomicrographs and 
histological scores of H&E-stained (***, P < 0.0001) and PAS-stained (***, P = 0.0004) sections. Error bars depict means of groups. Results are means ± SEM 
(n = 5–7 mice per group in two independent experiments). Bars, 100 µm. (E) DLN cells were restimulated ex vivo with OVA. Proliferation was measured (***,  
P = 0.0002). IL-4 (***, P < 0.0001), IL-13 (***, P < 0.0001), and IL-10 (***, P = 0.0008) in supernatants are shown. Results are shown as means ± SEM (n = 5–7 
mice per group in two separate experiments). (F) OVA-specific IgE (**, P = 0.0009), IgG1 (P = 0.1259), and IgG2a (P = 0.4556) in the sera of mice. Results are 
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neutralization systemically exacerbates EAE (Veldhoen et al., 
2006), and systemic (i.p.) TGF-1 administration protects 
from disease (Johns et al., 1991; Kuruvilla et al., 1991; Johns 
and Sriram, 1993). TGF-1 acts similarly in models of rheu-
matoid arthritis (Allen et al., 1990; Brandes et al., 1991). Dual 
effects depending on the route of administration have been 
also described for IL-10 in models of pneumococcal meningi-
tis and endotoxin-induced uveitis (Rosenbaum and Angell, 
1995; Koedel et al., 1996). Collectively, our studies and those 
by Hardy et al. (2006) emphasize the complex roles of activin-
A in the regulation of the immune response.
Importantly, our data reveal that activin-A’s immuno-
suppressive effects were associated with induction of antigen-
specific regulatory T cells. Strikingly, these activin-A–induced 
suppressor T cells inhibited the robust response of KJ1-
26+CD4+ T cells to the OVA323-339 peptide in vitro and 
suppressed responses of other untreated Th cells upon adop-
tive cotransfer in vivo. Activin-A–induced regulatory T cells 
were CD4+CD25Foxp3. A very recent study demon-
strated that TGF-1–induced conversion of CD4+CD25 T 
cells into CD4+CD25+Foxp3+ T cells in vitro could be fur-
ther enhanced if activin-A was added in the medium (Huber 
et al., 2009). However, activin-A was not essential for TGF-
1–induced Foxp3 expression, as neutralization by follistatin 
or anti–activin-A antibody had no effect on CD4+Foxp3+ T 
cell numbers. Moreover, the presence of low levels of TGF-
1 in activin-A–treated cultures was essential for Foxp3 in-
duction, supporting the notion that activin-A alone does not 
induce considerable Foxp3 expression.
Notably, activin-A induced the generation of a popula-
tion of CD4+IL-10+ T cells, possibly representing Tr1-like 
T regulatory cells. In support, activin-A treatment increased 
IL-10 levels in primary CD4+ T cell cultures. Moreover, 
our in vitro blocking studies revealed that enhanced IL-10 
production represents one of the mechanisms of activin- 
A–induced Th suppression. However, IL-10 levels were 
unaltered or even decreased during activin-A–mediated sup-
pression of secondary Th2 effector responses. This should 
not come as a surprise, because, in this setting, IL-10 (along 
with IL-4 and IL-13) acts predominantly as part of the effec-
tor Th2 cytokine profile and its levels follow the general 
Th2 cell suppression (Wills-Karp, 1999).
In addition, activin-A may induce other suppressive Th 
cell populations. This possibility explains our finding that 
blocking of IL-10 did not completely reverse the suppressive 
function of activin-A–induced regulatory Th cells. Further-
more, TGF-1 blockade also partially reversed activin- 
A–mediated Th suppression. Overall, it is conceivable that 
activin-A induces both IL-10–producing regulatory T cells 
and other non–IL-10–producing suppressor T cells. The 
the latter study used a different experimental protocol that 
involved several OVA/alum immunizations and a single 
challenge, whereas they depleted activin-A not only during 
challenge but at both phases of the allergic response. Alterna-
tively, or in conjunction, these differences may be, at least 
partly, caused by the use of different activin-A neutralizing 
antibodies. For example, it is possible that these antibodies 
blocked distinct activin-A epitopes, leading to different re-
ceptor-mediated responses. Nevertheless, in support of the 
suppressive effects of endogenous activin-A on IgE responses, 
we showed that systemic administration of r-activin-A into 
allergic mice right before pulmonary OVA challenge induced 
a striking (more than threefold) decrease in OVA-specific IgE 
levels. This was accompanied by significantly suppressed Th2 
systemic responses and protection against allergic airway dis-
ease. Collectively, our data reveal that administration of r- 
activin-A can be an effective therapeutic protocol for Th2-driven 
experimental asthma.
In a different study, local (pulmonary) administration of 
follistatin, an inhibitor of activin-A, during allergic airway 
inflammation decreased Th2 cytokines and mucus produc-
tion, pointing to proinflammatory effects of activin-A locally 
(Hardy et al., 2006). The different findings between our studies 
and the aforementioned ones may be, at least partly, caused 
by the use of distinct activin-A inhibitors. We administered a 
specific anti–activin-A neutralizing antibody, whereas Hardy 
et al. (2006) administered follistatin, an approach that does 
not directly address the effects of activin-A, as follistatin neu-
tralizes all activins and certain bone morphogenetic proteins 
(Vale et al., 1988; Harrison et al., 2005; Xia and Schneyer, 
2009). Moreover, considering that other activins and bone 
morphogenetic proteins are also induced in the lungs of mice 
and humans with asthma (Rosendahl et al., 2001; Rosendahl 
et al., 2002; Kariyawasam et al., 2008), it is plausible that the 
observed differences are also related to other follistatin func-
tions, such as the inhibition of these proteins.
Activin-A may also exert distinct in vivo effects depending 
on the route of administration or the site of overexpression. In 
fact, in contrast to the suppressive effects of systemic activin-A 
administration on allergic disease, we have showed that local 
(pulmonary) administration of r-activin-A enhances Th2 ef-
fector responses and exacerbates certain disease features (un-
published data). These findings point to proinflammatory effects 
of excessive amounts of activin-A locally, a feature shared by 
several cytokines, including immunoregulatory ones. For ex-
ample, TGF-1 blockade locally prevents the onset of experi-
mental autoimmune encephalomyelitis (EAE) (Veldhoen et al., 
2006), and overexpression in the brain results in more severe 
EAE, pointing to a proinflammatory role for this cytokine 
(Wyss-Coray et al., 1997; Luo et al., 2007). In contrast, TGF-1 
means ± SEM (n = 5–7 mice per group in two independent experiments). (G) Flow cytometry panels of gated CD3CD11c+ DLN cells from recipient mice 
stained for I-Ad. Numbers above boxed areas indicate the percentage of DLN cells in the outlined gate. The mean fluorescence intensity (MFI) of 
CD3CD11c+I-Ad+ cells in DLNs of mice that received CD4+ T cells treated with PBS or r-activin-A is depicted (***, P < 0.0001). Values are means ± SEM (n = 
5–7 mice per group in two separate experiments). Eos, eosinophils; FS, forward scatter; LMs, lymphomononuclears; Macs, macrophages; Neuts, neutrophils.
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activin-A–induced regulatory T cells suppress Th2 effector re-
sponses and, of clinical relevance, decrease allergen-specific IgE. 
Besides naturally occurring or inducible Foxp3+ T regulatory 
cells, several studies have shown the existence of antigen-specific 
Foxp3 suppressor T cells that are of critical importance, as they 
chemokine CXCL12 was recently found to inhibit EAE in a 
similar fashion (Meiron et al., 2008).
Our present studies also revealed that activin-A–induced 
regulatory T cells can confer protection against AHR and al-
lergic airway disease after adoptive transfer in vivo. In addition, 
Figure 6. In vivo administration of r-activin-A during pulmonary allergen challenge is protective against allergic airway disease. (A) BAL 
differentials from mice treated with r-activin-A or PBS, or from the alum controls are expressed as means ± SEM (n = 4–6 mice per group in two sepa-
rate experiments; **, P = 0.0021; ***, P < 0.0001). Statistical significance was obtained by an unpaired Student’s t test. (B) AHR is depicted. Results shown 
for PenH are expressed as means (n = 4–6 mice per group in two separate experiments). Data were analyzed by two-way ANOVA for repeated measures, 
followed by an unpaired Student’s t test (*, P = 0.0095; **, P = 0.0054). (C) Representative photomicrographs and histological scores of H&E-stained (**, 
P = 0.0085) and PAS-stained (**, P = 0.0015) sections. Error bars depict means of groups. Results are shown as means ± SEM (n = 4–6 mice per group in 
two separate experiments). Bars, 100 µm. (D) DLN cells were restimulated ex vivo with OVA. Proliferation was measured (***, P < 0.0001). IL-4 (***, P < 
0.0001), IL-13 (***, P < 0.0001), and IL-10 (***, P < 0.0001) in supernatants are shown. Results are means ± SEM (n = 4–6 mice per group from two inde-
pendent experiments). (E) OVA-specific IgE (*, P = 0.0119), IgG1 (**, P = 0.0081), and IgG2a in the sera of mice. Results are shown as means ± SEM  
(n = 4–6 mice per group in two independent experiments). Eos, eosinophils; LMs, lymphomononuclears; Macs, macrophages; Neuts, neutrophils.
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in lung DLNs. Thus, it is plausible that activin-A also sup-
presses Th responses through regulation of DC function. In 
fact, activin-A induces in vitro a dramatic reduction on both 
MHC class II and CD86 co-stimulatory molecule expression 
on mouse CD11c+ DCs (unpublished data). In support, recent 
studies using human DCs have shown that activin-A prevents 
cytokine-induced HLA-DR up-regulation and promotes a 
tolerance-inducing DC phenotype (Segerer et al., 2008).
confer protection against immune-mediated diseases, i.e., in ex-
perimental models of multiple sclerosis and inflammatory bowel 
disease (Roncarolo et al., 2006; Shevach, 2006; Sakaguchi and 
Powrie, 2007). Hence, the emergence of factors, such as activin-
A, that induce suppressor T cells protective against Th-linked 
diseases is of critical therapeutic importance.
Interestingly, the suppressive effects of activin-A–treated T 
cells were associated with a striking decrease of DC maturation 
Figure 7. Decreased expression of activin-A’s signaling components in allergic asthma. (A) Representative photomicrographs showing expression 
of activin-A and ALK4 in bronchial biopsies from healthy individuals and asthmatics. The specific staining for activin-A and ALK4 is depicted in red, whereas 
nuclei are blue (in activin-A photos). Red arrows indicate positively stained epithelial cells and black arrows point to positively stained subepithelial cells. 
Photomicrographs are representative from experiments performed on lung biopsies obtained from asthmatics (n = 15) and healthy individuals (n = 6). 
Immunostaining was performed once for each lung section. Bars, 100 µm. (B) Percentages of activin-A+ (**, P = 0.0355), ALK4+, and act-RIIA+ (***, P = 
0.0008) bronchial epithelial cells from asthmatics (n = 15) or healthy individuals (n = 6). For each biopsy, data were obtained counting positively stained 
epithelial cells along the entire basement membrane. Numbers of activin-A+ (*, P = 0.0045), ALK4+ (**, P = 0.0011), and act-RIIA+ (***, P = 0.0007) subepithe-
lial cells were determined by counting the entire section in each biopsy and are expressed as cells per square millimeter. Immunostaining was performed 
once for each lung section. Cell counts are presented as medians ± interquartile range. Statistical analysis was performed with the Mann-Whitney U test.
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of Athens’s Animal Facility. Procedures were in accordance with the United 
States National Institutes of Health Statement of Compliance (Assurance) 
with Standards for Humane Care and Use of Laboratory Animals (no. 
A5736-01) and with the European Union Directive 86/609/EEC on the 
protection of animals used for experimental purposes.
Experimental protocol of acute allergic airway inflammation. Acute 
allergic airway inflammation was induced in mice using OVA in alum. In 
brief, BALB/c mice were sensitized with OVA at a concentration of 0.01 
mg/mouse in 0.2 ml alum i.p. on days 0 and 12. Control mice received the 
same volume of PBS in alum (alum controls). Subsequently, all mice re-
ceived three challenges with aerosolized OVA (5% for 20 min) via the air-
ways between days 18 and 20. For blocking experiments, mice also received 
an affinity-purified polyclonal neutralizing antibody against mouse activin-A 
(R&D Systems) i.p. at a dose of 20 µg/mouse, 2–3 h before each OVA chal-
lenge. Other groups of OVA-challenged mice received similar doses of iso-
type control Ig (R&D Systems). In other experiments, mice received i.p. 
two doses (1.125 µg/mouse/day) of r-activin-A (R&D Systems) or PBS, 4–5 h 
before each OVA challenge. The optimal dose of r-activin-A was deter-
mined after titration experiments and was over endogenous activin-A levels 
in lungs and DLNs of allergic mice as measured by ELISA. Mice were eutha-
nized 48 h after the final OVA challenge.
AHR. AHR was measured in mice 24 h after the final OVA challenge (day 
21) by whole-body plethysmography (Buxco Research Systems) to calculate 
enhanced pause (PenH). Responses to inhaled methacholine at concentra-
tions of 3–100 mg/ml were measured for 1 min, as described previously 
(Xanthou et al., 2007).
Analysis of BAL. BAL harvesting was performed as previously described 
(Xanthou et al., 2007). In brief, inflammatory cells were obtained by cannu-
lation of the trachea and lavage of the airway lumen with PBS. Cytospin 
slides were prepared by Wright-Giemsa staining. All differential counts were 
performed blind and in a randomized order at the end of the study.
Lung histology. 4-µm paraffin-embedded sections were stained with he-
matoxylin and eosin (H&E) to evaluate lung infiltration, as described previ-
ously (Xanthou et al., 2007). A semiquantitative scoring system was used to 
grade the size of lung infiltrates, whereby +5 signified a large (>3 cells–deep) 
widespread infiltrate around the majority of vessels and bronchioles, and +1 
signifies a small number of inflammatory foci. Goblet cells were counted on 
periodic acid–Schiff (PAS)–stained lung sections using an arbitrary scoring 
system. In brief, PAS-stained goblet cells in airway epithelium were mea-
sured double blind using a numerical scoring system (0, <5%; 1, 5–25%; 2, 
25–50%; 3, 50–75%; and 4, >75% goblet cells). The sum of the airway scores 
from each lung was divided by the number of airways examined (20–30 per 
mouse) and expressed as mucus score in arbitrary units.
Human subjects. 15 individuals with atopic asthma with a 15% increase in 
forced expiratory volume in 1 s (FEV1) to 2 agonist, or a methacholine 
PC20 of ≤8 mg/ml were recruited. The median age was 25 yr (range = 19–
46 yr), with FEV1% predicted to be 97% (range = 75.4–125.7%) with a 
methacholine PC20 of 2.1 mg/ml (range = 2–3.6 mg/ml; geometric mean ± 
95% confidence interval). All subjects demonstrated positive skin prick tests 
to aeroallergens (ALK). The study design is previously described (Phipps 
et al., 2004; Kariyawasam et al., 2007). Six healthy volunteers with no his-
tory of asthma or atopy with a median age of 30.5 yr (range = 27–42 yr), and 
with a predicted FEV1% of 100.4% (range = 80–104.3%) with a methacho-
line PC20 of >16 mg/ml were included. The study was approved by the 
Royal Brompton and Harefield Hospital Ethics Committee, and subjects 
gave written informed consent.
Immunohistochemistry. Human lung biopsies were collected in PBS, and 
transferred into 4% paraformaldehyde (Sigma-Aldrich) and then to 15% su-
crose (Sigma-Aldrich), as previously described (Hamid et al., 1991; Robinson 
We were initially surprised that bronchial epithelial and 
infiltrating subepithelial cells in lung biopsies from asthmatic 
individuals exhibited enhanced activin-A expression. Our 
findings, as well as those from other studies, also revealed in-
creased activin-A expression by Th2 cells and in the lungs 
of allergic mice (Rosendahl et al., 2001; Hardy et al. 2006; 
Karagiannidis et al., 2006; Ogawa et al., 2006). Nevertheless, 
it is not unusual to have increased expression of immunosup-
pressive mediators during active inflammatory conditions. For 
example, TGF-1 is increased in the lungs of asthmatics 
(Chakir et al., 2003; Flood-Page et al., 2003), whereas up-
regulation of B-crystallin (Ousman et al., 2007) and osteo-
pontin (Xanthou et al., 2007) is observed in multiple sclerosis 
and asthma, respectively. Importantly, the increase in activin-
A was counterbalanced by decreased expression of activin-A’s 
receptors, ALK4 and Act-RIIA and -RIIB, in infiltrating 
mononuclear cells of asthmatics. This is indicative of reduced 
activin-A signaling in infiltrating leukocytes, pointing to de-
creased immunoregulation. In support, blockade of ALK4 
significantly enhanced Th2 responses in our experiments. 
Thus, activin-A up-regulation in the allergen-challenged lung 
may be part of an inherent protective mechanism, as also sug-
gested by the exacerbation of allergic airway disease upon 
activin-A neutralization before challenge. Finally, adoptive 
transfers of regulatory CD4+CD25+ T cells in sensitized mice 
not only protected from allergic airway disease (Kearley et al., 
2005) but also resulted in significant increase in lung activin-A 
levels (unpublished data).
Although both activin-A and TGF-1 belong to the 
same family of cytokines, it would be unjust to have them 
considered as redundant during inflammatory processes, as 
also suggested by several studies (Ogawa et al., 2000; Werner 
and Alzheimer, 2006; Le et al., 2007; Ogawa et al., 2008; 
Robson et al., 2009). In fact, our experiments reveal that in 
vivo blockade of activin-A resulted in significant exacerba-
tion of allergic airway disease despite the presence of endog-
enous TGF-1. Moreover, we demonstrate that activin-A 
and TGF-1 induce different regulatory T cell subsets, indi-
cating that these two cytokines may also operate through 
distinct suppressive mechanisms. These findings suggest that, 
at least in our experimental settings, activin-A has a distinct 
(to TGF-1) role.
Our findings introduce activin-A as a new member in the 
team of immune response regulation factors. Moreover, its 
implicit protective role in acute allergic airway disease places 
activin-A as a therapeutic target for allergic asthma. The role 
of activin-A in several facets of regulatory T cell biology, in-
cluding generation, maintenance, and function, is of great 
importance and remains to be further elucidated. Finally, 
considering its suppressive effects on Th1-driven responses, 
an involvement of activin-A in the regulation of autoimmu-
nity is highly probable and merits closer examination.
MATERIALS AND METHODS
Mice. BALB/c, BALB/c-Rag-1/, and OVA-specific T cell receptor 
transgenic DO11.10 mice were purchased from the Jackson Laboratory. 
Mice were housed at the Biomedical Research Foundation of the Academy 
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recipients were sensitized with OVA/alum and euthanized 10 d later. DLN 
cells were stimulated with the OVA323-339 peptide and T cell responses 
were measured.
In other experiments, 4 × 106 CD4+ T cells/mouse, obtained as de-
scribed, were adoptively transferred i.v. into BALB/c mice. 24 h later, mice 
were sensitized with OVA/alum, and 7 d later they received two challenges 
with aerosolized OVA (5% for 20 min).
Determination of serum antibody concentration. OVA-specific IgE, 
IgG1, and IgG2a serum antibodies were measured by ELISA, as previously 
described (Xanthou et al., 2007). Hyperimmune serum from OVA-alum–
sensitized and OVA-challenged BALB/c mice was used for the IgE, IgG1, 
and IgG2a standards.
Flow-cytometric analysis. Cells were stained with antibodies to CD4, 
CD3, KJ1-26, CD25, CD11c, I-Ad, CD-86, IL-10 (BD), and T1/ST2 (MD 
Biosciences). For intracellular IL-10 staining, CD4+ T or CD4+KJ1-26+  
T cells were stimulated for 24 h with anti-CD3 or OVA323-339 peptide and 
stained as previously described (Fitzgerald et al., 2007). In brief, cells were 
restimulated for 4 h with 10 ng/ml PMA (Sigma-Aldrich), 250 ng/ml iono-
mycin (Sigma-Aldrich), and 1 µl/ml GolgiStop (BD), followed by surface 
and intracellular staining according to the manufacturer’s instructions (BD). 
For intracellular Foxp3 staining, CD4+ T cells were stimulated with 2 µg/ml 
anti-CD3, 2 µg/ml anti-CD28, and 20 U/ml rIL-2 for 3 d. Cells were 
washed and stained with conjugated antibodies to CD4, CD3, and Foxp3 
according to the manufacturer’s instructions (eBioscience). Sorted (CD4+ 
CD25CD62L+) T cells from DO11.10 mice stimulated with OVA323-339 
peptide–loaded bone marrow–derived DCs were also used. In other experi-
ments, DLN cells were harvested from OVA323-339 peptide/alum–immu-
nized DO11.10 mice and restimulated ex vivo for 3 d with OVA323-339 
peptide. In others, DLN cells from OVA/alum–sensitized BALB/c mice 
were stimulated ex vivo with OVA for 4 d and rested in rIL-2 for 6 d before 
FoxP3 staining. To perform the FACS analysis, we used a cytometer 
(Cytomics FC 500; Beckman Coulter). Cell death was determined by flow 
cytometry using annexin V/PI staining (BD).
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